Iteos Therapeutics IncNASDAQ:ITOS
- LAST PRICE36.0900
- TODAY'S CHANGE (%)-1.5600 (-4.1434%)
- Bid / Lots0.0100/ 5
- Ask / Lots44.0000/ 9
- Open / Previous Close37.4100 / 37.6500
- Day Range
- 52 Week Range
- Volume512,970
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ITOS |
|---|---|---|
| 09:32 ET | 8122 | 37.0025 |
| 09:33 ET | 200 | 37.2661 |
| 09:39 ET | 300 | 37.56 |
| 09:42 ET | 12499 | 37.305 |
| 09:48 ET | 2300 | 37.02 |
| 09:50 ET | 758 | 37.075 |
| 09:55 ET | 4538 | 36.9 |
| 09:57 ET | 100 | 36.785 |
| 10:00 ET | 1094 | 37.09 |
| 10:02 ET | 3513 | 36.935 |
| 10:04 ET | 1200 | 36.71 |
| 10:06 ET | 3600 | 36.975 |
| 10:08 ET | 1901 | 36.9 |
| 10:09 ET | 5618 | 36.845 |
| 10:11 ET | 100 | 36.84 |
| 10:13 ET | 1786 | 36.66 |
| 10:15 ET | 5463 | 36.585 |
| 10:18 ET | 5581 | 36.82 |
| 10:20 ET | 2503 | 36.82 |
| 10:22 ET | 2000 | 36.99 |
| 10:24 ET | 100 | 36.84 |
| 10:26 ET | 1641 | 37.055 |
| 10:27 ET | 1400 | 37.12 |
| 10:29 ET | 14851 | 37.05 |
| 10:31 ET | 1160 | 36.95 |
| 10:33 ET | 800 | 36.99 |
| 10:36 ET | 3114 | 37.135 |
| 10:38 ET | 3400 | 37.3 |
| 10:40 ET | 18215 | 37.175 |
| 10:42 ET | 20751 | 37.5 |
| 10:44 ET | 15545 | 37.21 |
| 10:45 ET | 1952 | 37.02 |
| 10:47 ET | 1800 | 36.68 |
| 10:49 ET | 2781 | 37.18 |
| 10:54 ET | 700 | 37.17 |
| 10:56 ET | 100 | 37.38 |
| 10:58 ET | 400 | 37.19 |
| 11:00 ET | 100 | 37.29 |
| 11:02 ET | 1000 | 37.4 |
| 11:03 ET | 100 | 37.27 |
| 11:05 ET | 100 | 37.235 |
| 11:09 ET | 200 | 37.43 |
| 11:12 ET | 100 | 37.29 |
| 11:14 ET | 100 | 37.4 |
| 11:16 ET | 300 | 37.14 |
| 11:18 ET | 300 | 37.275 |
| 11:20 ET | 100 | 37.36 |
| 11:21 ET | 600 | 37.43 |
| 11:23 ET | 400 | 37.54 |
| 11:25 ET | 400 | 37.36 |
| 11:27 ET | 1400 | 37.315 |
| 11:30 ET | 1300 | 37.38 |
| 11:32 ET | 900 | 37.14 |
| 11:34 ET | 100 | 37.17 |
| 11:36 ET | 1666 | 37.08 |
| 11:38 ET | 1150 | 36.87 |
| 11:39 ET | 1004 | 36.78 |
| 11:45 ET | 500 | 36.82 |
| 11:48 ET | 100 | 36.95 |
| 11:50 ET | 600 | 36.59 |
| 11:52 ET | 600 | 36.87 |
| 11:54 ET | 300 | 36.78 |
| 11:56 ET | 100 | 36.835 |
| 11:57 ET | 600 | 36.89 |
| 11:59 ET | 600 | 36.75 |
| 12:03 ET | 100 | 36.83 |
| 12:08 ET | 400 | 36.835 |
| 12:10 ET | 400 | 36.76 |
| 12:12 ET | 300 | 36.62 |
| 12:14 ET | 400 | 36.48 |
| 12:21 ET | 200 | 36.25 |
| 12:24 ET | 100 | 36.23 |
| 12:26 ET | 1673 | 36.5 |
| 12:28 ET | 300 | 36.34 |
| 12:30 ET | 100 | 36.36 |
| 12:32 ET | 100 | 36.23 |
| 12:33 ET | 400 | 36.38 |
| 12:35 ET | 887 | 36.53 |
| 12:37 ET | 1007 | 36.35 |
| 12:42 ET | 341 | 36.46 |
| 12:46 ET | 400 | 36.57 |
| 12:48 ET | 600 | 36.41 |
| 12:50 ET | 500 | 36.54 |
| 12:51 ET | 743 | 36.278 |
| 12:55 ET | 300 | 36.32 |
| 12:57 ET | 100 | 36.41 |
| 01:00 ET | 558 | 36.31 |
| 01:02 ET | 200 | 36.335 |
| 01:08 ET | 400 | 36.25 |
| 01:09 ET | 300 | 36.26 |
| 01:11 ET | 300 | 36.35 |
| 01:13 ET | 300 | 36.31 |
| 01:15 ET | 100 | 36.34 |
| 01:18 ET | 486 | 36.2 |
| 01:20 ET | 300 | 36.09 |
| 01:27 ET | 1026 | 36.13 |
| 01:31 ET | 806 | 36.2 |
| 01:33 ET | 440 | 36.07 |
| 01:38 ET | 1000 | 36.15 |
| 01:40 ET | 100 | 36.205 |
| 01:42 ET | 600 | 36.35 |
| 01:45 ET | 350 | 36.13 |
| 01:47 ET | 3441 | 36.28 |
| 01:49 ET | 100 | 36.26 |
| 01:51 ET | 600 | 36.31 |
| 01:54 ET | 1301 | 36.35 |
| 01:56 ET | 500 | 36.385 |
| 01:58 ET | 100 | 36.33 |
| 02:00 ET | 300 | 36.34 |
| 02:02 ET | 500 | 36.255 |
| 02:03 ET | 1100 | 36.32 |
| 02:05 ET | 900 | 36.32 |
| 02:07 ET | 1550 | 36.55 |
| 02:09 ET | 100 | 36.515 |
| 02:14 ET | 761 | 36.56 |
| 02:16 ET | 400 | 36.48 |
| 02:18 ET | 100 | 36.59 |
| 02:20 ET | 100 | 36.58 |
| 02:21 ET | 900 | 36.61 |
| 02:25 ET | 500 | 36.58 |
| 02:27 ET | 1200 | 36.32 |
| 02:30 ET | 100 | 36.56 |
| 02:32 ET | 100 | 36.4 |
| 02:34 ET | 100 | 36.47 |
| 02:36 ET | 900 | 36.47 |
| 02:38 ET | 1500 | 36.7 |
| 02:39 ET | 600 | 36.78 |
| 02:41 ET | 37022 | 36.76 |
| 02:43 ET | 300 | 36.755 |
| 02:45 ET | 200 | 36.755 |
| 02:48 ET | 100 | 36.82 |
| 02:50 ET | 308 | 36.93 |
| 02:52 ET | 200 | 36.92 |
| 02:54 ET | 200 | 36.74 |
| 02:56 ET | 100 | 36.735 |
| 02:57 ET | 600 | 36.67 |
| 02:59 ET | 300 | 36.48 |
| 03:03 ET | 500 | 36.48 |
| 03:06 ET | 200 | 36.47 |
| 03:08 ET | 2032 | 36.46 |
| 03:10 ET | 905 | 36.47 |
| 03:14 ET | 305 | 36.38 |
| 03:15 ET | 400 | 36.36 |
| 03:17 ET | 738 | 36.42 |
| 03:21 ET | 300 | 36.5 |
| 03:24 ET | 700 | 36.54 |
| 03:26 ET | 900 | 36.51 |
| 03:28 ET | 7500 | 36.35 |
| 03:30 ET | 800 | 36.25 |
| 03:33 ET | 3244 | 36.29 |
| 03:37 ET | 500 | 36.44 |
| 03:39 ET | 200 | 36.43 |
| 03:42 ET | 3600 | 36.4 |
| 03:44 ET | 800 | 36.385 |
| 03:46 ET | 3781 | 36.15 |
| 03:50 ET | 3205 | 36.39 |
| 03:51 ET | 5900 | 36.2 |
| 03:53 ET | 3380 | 36.14 |
| 03:55 ET | 5436 | 36.11 |
| 03:57 ET | 9430 | 36.07 |
| 04:00 ET | 79019 | 36.09 |
Jan 10, 2022
BRIEF-Iteos Promotes Yvonne Mcgrath To Chief Scientific Officer
BRIEF-Iteos Provides Clinical Development Plans And Promotes Yvonne Mcgrath, Ph.D. To Chief Scientific Officer
iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
iTeos Provides Clinical Development Plans and Promotes Yvonne McGrath, Ph.D. to Chief Scientific Officer
Jan 7, 2022
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Iteos Therapeutics Inc | 1.3B | 122.9x | --- |
Prometheus Biosciences Inc | 1.3B | 0.0x | --- |
Nuvation Bio Inc | 1.2B | -13.1x | --- |
Atara Biotherapeutics Inc | 1.2B | -3.9x | --- |
Lyell Immunopharma Inc | 1.3B | 0.0x | --- |
Celldex Therapeutics Inc | 1.3B | -15.9x | --- |
Company Information
iTeos Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of differentiated immuno-oncology therapeutics for patients. The Company's pipeline includes two clinical-stage programs: EOS-448 and Inupadenant (EOS-850). The Company’s lead antibody product candidate, EOS-448, is an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), an immune checkpoint with multiple mechanisms of action, which leads to immunosuppression. Its EOS-850, is designed as a selective small molecule antagonist of the adenosine A2a receptor (A2AR) in the adenosine triphosphate (ATP) adenosine pathway. The Company is conducting an open-label multi-arm Phase I/II clinical trial of inupadenant in adult cancer patients with advanced solid tumors.
Contact Information
- Headquarters
- 139 Main StreetCAMBRIDGE, MA, United States 02142
- Phone
- 857-204-4583
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- David Hallal
- Chief Executive Officer, Director
- Michel Detheux
- Chief Financial Officer
- Matthew Gall
- Chief Operating Officer
- Matthew Call
- Vice President - Research and Development
- Yvonne Mcgrath
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
|---|---|
Revenue (TTM) | $104.3M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $0.29 |
Book Value | $9.22 |
P/E Ratio | 122.9x |
Price/Sales (TTM) | 12.2 |
Price/Cash Flow (TTM) | 82.9x |
Operating Margin | 15.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
